Compazine, the brand-name version of prochlorperazine, was discontinued for commercial reasons, not because of safety concerns or an FDA recall. The manufacturer stopped producing the branded product after generic versions became widely available, making the brand name financially unviable. The active drug itself, prochlorperazine, remains FDA-approved and is still prescribed today in generic form.
This is a common pattern in the pharmaceutical industry. Once a drug loses patent protection and generic competitors enter the market, the brand-name version often can’t justify its higher price. The manufacturer quietly exits, but the medication lives on under its generic name.
What Compazine Is Used For
Prochlorperazine belongs to a class of older psychiatric medications, but its primary use in modern medicine is as an anti-nausea drug. It works by blocking dopamine receptors in the brain, which helps suppress the signals that trigger nausea and vomiting. It’s FDA-approved for treating severe nausea and vomiting from various causes, and it’s also approved for managing non-psychotic anxiety and schizophrenia, though those uses are far less common today.
In cancer care, prochlorperazine still appears in clinical guidelines as an option for preventing nausea from lower-risk chemotherapy regimens. Dana-Farber Cancer Institute’s treatment guidelines, for example, list it alongside newer drugs as a prophylactic choice before certain chemotherapy sessions. For higher-risk chemotherapy and radiation-induced nausea, newer medications like ondansetron (Zofran) have largely taken over as the first-line choice.
Generic Availability Today
Generic prochlorperazine tablets are still manufactured and dispensed at pharmacies, though the supply has thinned. Viatris, one of the major generic manufacturers, discontinued all of its prochlorperazine tablets in October 2022. As of recent reports, Cadista still produces 5 mg and 10 mg tablets. Injectable forms also exist but have faced intermittent shortages.
If your pharmacy tells you prochlorperazine is unavailable, it may be a supply issue with that particular manufacturer rather than a permanent disappearance of the drug. Your pharmacist can check whether another supplier has it in stock or whether an alternative anti-nausea medication makes sense.
Why Newer Alternatives Gained Ground
Compazine’s decline in popularity has less to do with one dramatic event and more to do with the arrival of drugs that work differently and carry fewer neurological risks. Ondansetron, which blocks serotonin rather than dopamine, became the go-to anti-nausea medication for many situations because it doesn’t cause the same movement-related side effects that prochlorperazine does.
Prochlorperazine is closely related to antipsychotic medications, and it shares their risk of causing involuntary muscle movements. These range from short-term reactions like muscle stiffness, restlessness, and spasms to a potentially irreversible condition called tardive dyskinesia, which involves repetitive, uncontrollable movements of the face and body. The risk of tardive dyskinesia increases with longer use and higher cumulative doses, but it can develop even after relatively brief treatment at low doses. Elderly women appear to be at the highest risk. Current cancer care guidelines recommend screening patients taking prochlorperazine at every visit for signs of postural abnormalities, unintentional movements, and restlessness.
The drug also carries a boxed warning (the FDA’s most serious label warning) regarding use in elderly patients with dementia-related psychosis. Clinical trial data across antipsychotic medications showed that elderly dementia patients treated with these drugs had a death rate of about 4.5% over 10 weeks, compared to 2.6% for patients on placebo. Most of these deaths were cardiovascular or infectious in nature. Prochlorperazine is not approved for treating dementia-related psychosis.
Restrictions in Children
Prochlorperazine has notable restrictions for pediatric use. It is contraindicated in children under 2 years old or weighing less than 20 pounds, and it cannot be used during pediatric surgery. Children with acute illnesses like chickenpox, measles, or stomach infections appear much more susceptible to severe involuntary muscle reactions than adults. There is also a concern that the drug’s neurological side effects can mimic or mask the symptoms of Reye’s syndrome, a rare but serious condition that affects the brain and liver in children recovering from viral infections.
Where Prochlorperazine Still Fits
Despite its side effect profile, prochlorperazine hasn’t disappeared from medical practice. It remains useful in specific situations: emergency departments still use it for severe nausea and acute migraines, and oncology guidelines include it as an option for lower-risk chemotherapy regimens. When the cause of a patient’s nausea is unknown, it’s listed alongside several other agents as a reasonable choice.
The key distinction in current practice is that prochlorperazine tends to be used for short-term or situational nausea rather than as ongoing daily therapy, which helps limit the risk of movement disorders. Clinicians also avoid combining it with other dopamine-blocking drugs, since stacking medications from the same class increases side effects without improving effectiveness. In refractory cases where nausea persists despite standard treatment, guidelines suggest rotating to a different drug class rather than adding more dopamine blockers.
So while the Compazine brand is gone, the drug itself is still around. It occupies a smaller, more targeted role than it once did, largely because better-tolerated alternatives now handle the bulk of anti-nausea prescribing.